BridgeBio Pharma (BBIO) Retained Earnings (2017 - 2026)
BridgeBio Pharma recorded quarterly Retained Earnings of -$8000.0 in Q1 2026, down 166.67% quarter-over-quarter from $12000.0 in Q4 2025.
BridgeBio Pharma's Retained Earnings history runs 10 years deep, the most recent figure standing at -$8000.0 for Q1 2026.
- In Q1 2026, Retained Earnings changed N/A year-over-year to -$8000.0; the TTM figure through Mar 2026 stood at -$8000.0 (changed N/A YoY), while the FY2025 annual figure was $12000.0, up 50.0% from the prior year.
- Retained Earnings came in at -$8000.0 for Q1 2026 at BridgeBio Pharma, down from $12000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $34000.0 in Q3 2023 to a low of -$3.6 billion in Q3 2025.
- A 5-year average of -$1.0 billion and a median of -$377500.0 in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings jumped 109.45% in 2023 and sank 72566720.0% in 2025, its largest moves.
- BridgeBio Pharma's Retained Earnings stood at -$328000.0 in 2022, then jumped by 109.45% to $31000.0 in 2023, then sank by 74.19% to $8000.0 in 2024, then soared by 50.0% to $12000.0 in 2025, then tumbled by 166.67% to -$8000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$8000.0, $12000.0, and -$3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | -3.63 Bn |
| Jun 30, 2025 | 1,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | -2.67 Bn |
| Mar 31, 2024 | -2.60 Bn |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | -2.22 Bn |
| Mar 31, 2023 | -2.06 Bn |
| Dec 31, 2022 | -328,000.00 |
| Sep 30, 2022 | -1.78 Bn |
| Jun 30, 2022 | -427,000.00 |
| Mar 31, 2022 | -1.63 Bn |
| Dec 31, 2021 | -132,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | -1.13 Bn |
| Mar 31, 2021 | -57,000.00 |
| Dec 31, 2020 | 192,000.00 |
| Sep 30, 2020 | -768.77 Mn |
| Jun 30, 2020 | 858,000.00 |
| Mar 31, 2020 | 726,000.00 |
| Dec 31, 2019 | 254,000.00 |
| Sep 30, 2019 | 152,000.00 |
| Jun 30, 2019 | -306.59 Mn |
| Mar 31, 2019 | -240.63 Mn |
| Dec 31, 2018 | -179.44 Mn |
| Dec 31, 2017 | -48.70 Mn |